---
title: "Sanofi collaborates with Shanghai Pharmaceutical to promote three vaccine products in certain broad markets"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/266470359.md"
description: "Sanofi collaborates with Shanghai Pharmaceuticals Holding to promote three vaccine products: Pantoea, Vaxneuvance, and Vaxzevria in certain markets starting from 2026. Sanofi is responsible for national import and distribution"
datetime: "2025-11-19T03:04:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/266470359.md)
  - [en](https://longbridge.com/en/news/266470359.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/266470359.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/266470359.md) | [繁體中文](https://longbridge.com/zh-HK/news/266470359.md)


# Sanofi collaborates with Shanghai Pharmaceutical to promote three vaccine products in certain broad markets

According to Sanofi, starting from January 1, 2026, Sanofi will leverage the capabilities of its local partner, Shanghai Pharmaceuticals Holding's wholly-owned subsidiary, Hongyao Technology, to provide academic promotion services for vaccination points of three vaccine products: Pentaxim® (pentavalent vaccine), Vaxigrip® (influenza vaccine), and Fluzone® (influenza vaccine) in certain broad market areas, further enhancing accessibility. Sanofi will continue to be responsible for the import, distribution, and all other regional academic promotion work for the three products nationwide. (Jiemian)

### Related Stocks

- [Sanofi (SNYNF.US)](https://longbridge.com/en/quote/SNYNF.US.md)
- [Sanofi (SNY.US)](https://longbridge.com/en/quote/SNY.US.md)

## Related News & Research

- [Sanofi Secures EU Conditional Marketing Approval for Graft-vs-Host Disease Medicine](https://longbridge.com/en/news/281129645.md)
- [Sanofi’s Sarclisa Subcutaneous Formulation Via On-Body Injector Recommended For EU Approval](https://longbridge.com/en/news/280786871.md)
- [Key facts: Japan OKs Dupixent for BP; Sanofi Starts GCC Drive](https://longbridge.com/en/news/280398017.md)
- [Japan Clears Sanofi, Regeneron's Dupixent as First Targeted Therapy for Rare Skin Disease](https://longbridge.com/en/news/280298002.md)
- [Sanofi Reports Positive Phase 3 Results For Amlitelimab In Atopic Dermatitis](https://longbridge.com/en/news/280884138.md)